Item 8.01 Other Events.

On January 18, 2022, Celularity Inc. issued a press release announcing the receipt of Fast Track Designation from the U.S. Food and Drug Administration, for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-101, in development for the first-line treatment of advanced HER2/neu positive gastric and gastroesophageal junction cancers.

A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:





99.1      Press Release of Celularity Inc. dated January 18, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses